Roche
RHHBY | OTC
$60.98
+$0.68 (+1.13%)
At close: Nov 16, 2026, 3:59 PM ET
$60.95
-$0.03 (-0.05%)
After-hours:
Nov 16, 2026, 4:00 PM ET
Roche Company Profile
Company profile explainedCompany Profile
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.
Key Executives
| Name | Position |
|---|---|
| Thomas Schinecker | Group Chief Executive Officer |
| Alan Hippe | Chief Financial Officer |
| Maria Cristina A. Wilbur | Chief People Officer |
| Boris L. Zaitra | Head of Corporate Business Development |
| Bruno Eschli | Head of Investor Relations |
| Claudia Bockstiegel | General Counsel |
| Nicolas Dunant | Head of Group Media Relations |
| Nina Schwab-Hautzinger | Head of Group Communications |
| Severin Schwan | Executive Chairman |
| Wafaa Mamilli | Chief Digital & Technology Officer |
Roche
| Country | Switzerland |
| IPO Date | Aug 20, 2003 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 103,249 |
| CEO | Thomas Schinecker |
Contact Details
Grenzacherstrasse 124 Basel,
BS 4070 Switzerland
Stock Details
| Ticker Symbol | RHHBY |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 771195104 |
| ISIN Number | US7711951043 |
| SIC Code | n/a |
Recent News
- 8 hours ago / globenewswire.comFDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer
- 9 hours ago / reuters.comUS FDA approves Roche's oral treatment for advanced breast cancer
- 16 hours ago / prnewswire.comRoche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories
- 18 hours ago / youtube.comChances of Jensen Huang returning to Nvidia 'very slim': David Roche
- 18 hours ago / businesswire.comFaeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
- 6 days ago / businesswire.comPerficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory Systems
- 15 days ago / prnewswire.comRoche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs
- 19 days ago / seekingalpha.comRoche: Valuation Leaves Limited Upside
- 21 days ago / globenewswire.comRoche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories
- 22 days ago / globenewswire.comBillions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
Add to Watchlist
Select watchlists to add or remove RHHBY